Page 261 - மருத்துவ அவசர ஊர்தி புதியது தெற்கு வேல்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(1) - Clinical utility of Axumin (fluciclovine F 18) being investigated in expanded areas of cancer imaging - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced that the first patient has been dosed in its Phase 3 REVELATE clinical trial of 18F-fluciclovine, a positron emission tomography (PET) imaging radiopharmaceutical being studied for potential use in detecting recurrent brain metastases. The REVELATE study is a Phase 3, multi-center, single-arm imaging study being conducted in the United States. Its purpose is to assess the diagnostic performance of 18F-fluciclovine PET in detecting recurrent brain metastases in patients previously treated with radiation therapy. The first patient dosed in the study was at Yale University, New Haven, Conn., under the auspices of Dr. Mariam Aboian, Assistant Professor of Radiology.

United statesUnited kingdomSamuelt chaoMariam aboianPeter gardinerPriscilla harlanJonathan allisKostenloser wertpapierhandelClare gidleyMike beyerYale universityEmory universityDrug administrationEmory university department of radiologySam brown incBracco group